Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal patterns of threat- and deprivation-based childhood adversity and their impact on adolescent drinking, smoking, and depression.

Child abuse & neglect·2026
Same author

E-Cigarette Quit Intention, Quit Attempt and Abstinence Among U.S. Adults.

Substance use & misuse·2026
Same author

Psychological Distress, Unmet Need for Mental Health, and Associated Simultaneous Alcohol and Cannabis Use, and Co-Occurring Disorders Among College Students.

Substance use & misuse·2026
Same author

Pathways from racial/ethnic discrimination experience to cannabis use intentions: a longitudinal study of the mediating roles of perceived accessibility and harm among preteens.

Journal of ethnicity in substance abuse·2026
Same author

Reciprocal relationships among youth social media use, internalizing symptoms, and substance use.

Drug and alcohol dependence·2026
Same author

Psychotropic medication continuation during pregnancy and risk of postpartum self-injurious thoughts and behaviors.

Journal of affective disorders·2025

Related Experiment Video

Updated: Apr 30, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K

Systemic corticosteroids are frequently prescribed for psoriasis.

Amir Al-Dabagh, Rana Al-Dabagh, Scott A Davis

    Journal of Cutaneous Medicine and Surgery
    |May 8, 2014
    PubMed
    Summary

    Systemic corticosteroids are frequently prescribed for psoriasis, despite guidelines advising against their use. This study found no change in their prescription trends over time, highlighting a need for more data on their risks and benefits.

    More Related Videos

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
    02:28

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

    Published on: March 1, 2024

    1.1K
    Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
    05:18

    Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

    Published on: May 26, 2023

    2.0K

    Related Experiment Videos

    Last Updated: Apr 30, 2026

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    38.4K
    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
    02:28

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

    Published on: March 1, 2024

    1.1K
    Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
    05:18

    Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

    Published on: May 26, 2023

    2.0K

    Area of Science:

    • Dermatology
    • Pharmacology
    • Public Health

    Background:

    • Major psoriasis treatment guidelines discourage the use of systemic corticosteroids.
    • Despite recommendations, the actual clinical practice regarding systemic corticosteroid use for psoriasis requires investigation.

    Purpose of the Study:

    • To determine the frequency of systemic corticosteroid prescriptions for psoriasis.
    • To analyze trends in systemic corticosteroid use for psoriasis over time.

    Main Methods:

    • Utilized National Ambulatory Medical Care Survey (NAMCS) data (1989-2010) to identify systemic medications for psoriasis.
    • Confirmed findings with MarketScan Medicaid data analysis (2003-2007).

    Main Results:

    • Systemic corticosteroids were prescribed in an estimated 650,000 out of 21 million psoriasis visits.
    • Corticosteroids were the second most common systemic medication prescribed for psoriasis, with no significant change in use over time.
    • Prednisone was prescribed more frequently than methotrexate or etanercept in MarketScan data.

    Conclusions:

    • Systemic corticosteroids remain a common psoriasis treatment despite guidelines.
    • There is a critical need for data on the risks and benefits of systemic corticosteroids in psoriasis management.
    • Physicians and patients require evidence-based information for informed treatment decisions.